Inflammation in multiple system atrophy

Marta Leńska-Mieciek; Natalia Madetko-Alster; Piotr Alster; Leszek Królicki; Urszula Fiszer; Dariusz Koziorowski

doi:10.3389/fimmu.2023.1214677

Inflammation in multiple system atrophy

Front Immunol. 2023 Jun 22:14:1214677. doi: 10.3389/fimmu.2023.1214677. eCollection 2023.

Authors

Marta Leńska-Mieciek¹, Natalia Madetko-Alster², Piotr Alster², Leszek Królicki³, Urszula Fiszer¹, Dariusz Koziorowski²

Affiliations

¹ Department of Neurology and Epileptology, Centre of Postgraduate Medical Education, Warsaw, Poland.
² Department of Neurology, Medical University of Warsaw, Warsaw, Poland.
³ Department of Nuclear Medicine, Medical University of Warsaw, Warsaw, Poland.

Abstract

Misfolding protein aggregation inside or outside cells is the major pathological hallmark of several neurodegenerative diseases. Among proteinopathies are neurodegenerative diseases with atypical Parkinsonism and an accumulation of insoluble fibrillary alpha-synuclein (synucleinopathies) or hyperphosphorylated tau protein fragments (tauopathies). As there are no therapies available to slow or halt the progression of these disea ses, targeting the inflammatory process is a promising approach. The inflammatory biomarkers could also help in the differential diagnosis of Parkinsonian syndromes. Here, we review inflammation's role in multiple systems atrophy pathogenesis, diagnosis, and treatment.

Keywords: inflammation; multiple system atrophy (MSA); neurodegeneration; synucleinopathies; tauopathies.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Inflammation
Multiple System Atrophy* / diagnosis
Multiple System Atrophy* / therapy
Parkinsonian Disorders*
Synucleinopathies*
Tauopathies* / pathology

Grants and funding

This work was financially supported by the Centre of Postgraduate Medical Education, Warsaw, Poland (project number: 501-1-014-16-22.